阿卡波糖与混合胰岛素联合应用的临床意义  

Combination Therapy with Acorbose and Mixed Insulin

作　　者：黄昭瑄[1] 黄昭穗[1] 李燕娃 尹秀英[1] 

机构地区：[1]解放军第174医院内分泌科,福建厦门361003

出　　处：《临床军医杂志》2008年第3期390-392,共3页Clinical Journal of Medical Officers

摘　　要：目的观察混合重组人胰岛素(诺和灵30R)与午餐加服阿卡波糖对午餐后2 h血糖及对糖化血红蛋白的影响。方法54例2型糖尿病人,随机分为对照组(单纯采用混合重组人胰岛素治疗)和治疗组(采用混合重组人胰岛素治疗)与午餐加服阿卡波糖治疗,查分组时及8周后的空腹血糖、三餐后血糖、糖化血红蛋白及血脂,进行统计学处理。结果8周时,治疗组的午餐及晚餐后血糖和糖化血红蛋白较对照组明显下降(P<0.05),血脂两组无明显变化(P>0.05)。结论午餐加服阿卡波糖,可改善诺和灵30R对午餐后血糖控制不良的缺陷。Objective To compare the efficacy of treatment between mixed insulin （Nov30R） alone and Nov30R plus acarbose at noon in the patients with type 2 diabetes who showed postprandial hyperglycemia. Methods A total of 54 subjects with type 2 diabetes were divided into acarbose - treated group （ n = 27 ） treated with Nov30R plus acarbose at noon for eight weeks and control group （ n = 27 ） treated with Nov30R alone, at random. Results Compared with that of the control group, the levels of post-lunch and post-supper glucose of the acarbose-treated group, as well as the level of glycosylated haemoglobin, decreased significantly （ P 〈 0.05 ）. There were no differences in the levels of fasting or post-breakfast blood glucose and fat between the two groups （ P 〉 0.05 ）. Conclusion The addition of acarbose to Nov30R at noon provides an efficacious treatment for better control of blood glucose.

关 键 词：诺和灵30R 阿卡波糖 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]